ARCHIVES

Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 3 | March 29, 2013

Download PDF Visit The Full Archive

Related Articles

Lasofoxifene Reduced Breast Cancer Risk In Postmenopausal Osteoporotic Women

November 26, 2010

What the Physician Pay Report Won’t Tell You

April 11, 2014

Critics of FDA misunderstand Bayesian analysis, statisticians say.

August 5, 2005

Tempero, Johnson Take ASCO Offices

June 6, 2003

Arsenic Compound Improves Survival Of Adults With APL

February 23, 2007

In Brief: Budget Timetable Puts Pressure On Congress To Complete Appropriations Before Oct. 1

January 30, 1976